0JW9 Stock Price, Chart, Stats & News

Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an intravenously administered small molecule. This therapy is designed to inhibit mitochondrial oxidative phosphorylation and aims to combat specific cancer types, including human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and other solid tumors.